Ara-290 (10 mg) Dosage & Research Protocol

Ara-290 (Cibinetide) is an 11-amino acid peptide derived from erythropoietin (EPO). Unlike full-molecule EPO, Ara-290 selectively activates the Innate Repair Receptor (IRR). This allows for potent anti-inflammatory, neuroprotective, and tissue-protective effects without increasing red blood cell production—making it a primary focus for research into neuropathy and chronic inflammation.

Quickstart Guide

• Purpose: Neuroprotection, nerve regeneration, and anti-inflammatory signaling.

• Concentration: Reconstitute with 2.0 mL of bacteriostatic water for a final concentration of 5 mg/mL.

• Target Maintenance Dose: 4 mg daily (administered subcutaneously).

• Easy Measuring: At 5 mg/mL, 10 units = 0.5 mg or 20 units = 1 mg on a U-100 insulin syringe.

Dosing Schedule & Titration

To optimize research data and monitor individual tolerance, this protocol follows a standard 1-week titration followed by a maintenance phase.

Week 1: Initial Titration Daily Dose: 2 mg Injection Volume: 40 Units (0.40 mL)

Weeks 2–16: Maintenance Phase Daily Dose: 4 mg Injection Volume: 80 Units (0.80 mL)

Note: Clinical studies found 4 mg to be the target therapeutic dose; no significant additional benefits were observed at higher doses.

Reconstitution & Storage

Maintaining the structural integrity of Ara-290 is essential for consistent research results.

Reconstitution Steps

1. Clean the vial stopper with an alcohol swab.

2. Slowly inject 2.0 mL of bacteriostatic water against the inner wall of the vial.

3. Gently swirl or roll the vial until the powder is fully dissolved. Do not shake.

Storage Guidelines

• Lyophilized (Dry): Refrigerate at 2–8 °C (35.6–46.4 °F) for up to 2 years, or freeze at −20 °C (−4 °F) for up to 3 years.

• Reconstituted (Liquid): Must be refrigerated at 2–8 °C (35.6–46.4 °F) and used within 28 days. Do not freeze the liquid solution.

Logistics: Supply Planning (10 mg Vials)

Because Ara-290 requires a high daily dose (4 mg), supply planning is critical. Each 10 mg vial provides 2.5 days of treatment at the maintenance dose.

8-Week Protocol

• Ara-290 (10 mg): 23 Vials (approximate)

• U-100 Insulin Syringes: 56 Count

• Bacteriostatic Water: 5 x 10 mL Bottles

• Alcohol Prep Pads: 2 Boxes (100ct)

12-Week Protocol

• Ara-290 (10 mg): 34 Vials (approximate)

• U-100 Insulin Syringes: 84 Count

• Bacteriostatic Water: 7 x 10 mL Bottles

• Alcohol Prep Pads: 2 Boxes (100ct)

16-Week Protocol

• Ara-290 (10 mg): 45 Vials (approximate)

• U-100 Insulin Syringes: 112 Count

• Bacteriostatic Water: 9 x 10 mL Bottles

• Alcohol Prep Pads: 3 Boxes (100ct)

Mechanism of Action

Ara-290 binds to the Innate Repair Receptor (IRR), which is distinct from the classical erythropoietin receptor.

• Tissue Repair: Binding triggers anti-apoptotic and anti-inflammatory signaling that protects tissues and encourages regeneration.

• Pain Modulation: Analgesic effects have been observed via immunomodulation and the direct inhibition of TRPV1 ion channels.

• No Blood Thickening: Because it does not bind to the classical EPO receptor, it does not stimulate red blood cell production, avoiding the cardiovascular risks associated with high EPO levels.

Potential Benefits & Observations

• Small Fiber Neuropathy: Clinical trials have shown significant regrowth in corneal nerve fiber density and improved neuropathic pain scores.

• Metabolic Health: Improvements in HbA1c and lipid profiles have been observed in studies involving diabetic neuropathy.

• Tolerability: Clinical data indicates high tolerability at 4 mg/day, with side effects generally limited to minor localized injection site reactions.

Injection Technique & Best Practices

• Route: Subcutaneous injection (SQ).

• Sites: Abdomen (at least 2 inches from the navel), outer thighs, or the back of the upper arms.

• Rotation: Essential to rotate sites daily to prevent lipohypertrophy (tissue hardening).

• Technique: Pinch the skin to isolate fat, insert the needle at 90°, and inject slowly. Ara-290 doses (0.80 mL) are larger than some other peptides; injecting slowly reduces discomfort.

Disclaimer: This guide is for educational and research purposes only. Ara-290 is not FDA-approved for human consumption. Always consult with a licensed professional before beginning any peptide research.